Open Forum Infectious Diseases,
Journal Year:
2022,
Volume and Issue:
9(3)
Published: Jan. 10, 2022
Abstract
Background
A
proposal
has
recently
been
advanced
to
change
the
traditional
definition
of
nonalcoholic
fatty
liver
disease
metabolic-associated
(MAFLD),
reflect
cluster
metabolic
abnormalities
that
may
be
more
closely
associated
with
cardiovascular
risk.
Long
coronavirus
2019
(COVID-19)
is
a
smoldering
inflammatory
condition,
characterized
by
several
symptom
clusters.
This
study
aims
determine
prevalence
MAFLD
in
patients
postacute
COVID
syndrome
(PACS)
and
its
association
other
PACS-cluster
phenotypes.
Methods
We
included
235
observed
at
single
university
outpatient
clinic.
The
diagnosis
PACS
was
based
on
≥1
symptoms:
respiratory,
neurocognitive,
musculoskeletal,
psychological,
sensory,
dermatological.
outcome
detected
transient
elastography
during
first
postdischarge
follow-up
visit.
time
hospital
admission
calculated
retrospectively
using
hepatic
steatosis
index.
Results
Of
patients,
162
(69%)
were
men
(median
age
61).
55.3%
37.3%
(P
<
.001).
Insulin
resistance
(odds
ratio
[OR]
=
1.5;
95%
confidence
interval
[CI],
1.14–1.96),
body
mass
index
(OR
1.14;
CI,
1.04–1.24),
2.54;
1.13–5.68)
independent
predictors
MAFLD.
number
clusters
inversely
0.86;
.76–0.97).
Thirty-one
(13.2%)
had
no
All
correlations
between
weak.
Conclusions
Metabolic-associated
highly
prevalent
after
discharge
represent
specific
phenotype,
potential
long-term
health
implications.
Metabolites,
Journal Year:
2022,
Volume and Issue:
12(4), P. 298 - 298
Published: March 29, 2022
Nonalcoholic
fatty
liver
disease
(NAFLD)
is
the
leading
cause
of
chronic
disease.
NAFLD
often
occurs
associated
with
endocrinopathies.
Evidence
suggests
that
endocrine
dysfunction
may
play
an
important
role
in
development,
progression,
and
severity.
Our
work
aimed
to
explore
summarize
crosstalk
between
different
organs,
their
hormones,
dysfunctions.
For
instance,
our
results
show
hyperprolactinemia,
hypercortisolemia,
polycystic
ovary
syndrome
seem
worsen
NAFLD’s
pathway.
Hypothyroidism
low
growth
hormone
levels
also
contribute
a
bidirectional
association
hypercortisolism
hypogonadism
pathway
looks
likely,
given
current
evidence.
Therefore,
we
concluded
it
appears
likely
there
link
several
disorders
other
than
typically
known
type
2
diabetes
mellitus
metabolic
(MS).
Nevertheless,
controversial
insufficient
evidence
this
area
knowledge.
Diabetes Obesity and Metabolism,
Journal Year:
2022,
Volume and Issue:
24(9), P. 1702 - 1720
Published: May 20, 2022
Nonalcoholic
fatty
liver
disease
(NAFLD)
and
osteoporosis
are
two
highly
prevalent
metabolic
diseases.
Increasing
experimental
evidence
supports
a
pathophysiological
link
between
NAFLD
osteoporosis.
A
key
feature
could
be
chronic,
low-grade
inflammation,
which
characterizes
possibly
affects
bone
metabolism.
In
this
context,
several
factors,
including
but
not
limited
to
receptor
activator
of
nuclear
factor
kappa-B
ligand,
osteoprotegerin,
osteopontin
osteocalcin,
may
serve
as
mediators.
the
clinical
setting,
most
all
epidemiological
indicates
that
is
associated
with
lower
mineral
density
or
in
adults.
Although
an
association
has
yet
been
established,
thus
remains
speculative,
pharmacological
considerations
already
exist.
Some
current
emerging
options
for
have
shown
possible
anti-osteoporotic
properties
(eg,
vitamin
E,
obeticholic
acid,
semaglutide),
while
others
pioglitazone,
canagliflozin)
increased
risk
fractures
avoided
patients
concomitant
osteoporosis,
especially
those
at
high
fracture
risk.
Conversely,
some
medications
(denosumab)
might
benefit
NAFLD,
(raloxifene)
adversely
affect
it
and,
consequently,
NAFLD.
If
medication
target
both
diseases
would
great
advancement.
This
review
summarizes
main
on
potential
focuses
treatment
derived
from
association.
Seminars in Liver Disease,
Journal Year:
2022,
Volume and Issue:
42(03), P. 379 - 400
Published: June 16, 2022
Nonalcoholic
steatohepatitis
(NASH)
is
a
burgeoning
global
health
crisis
that
mirrors
the
obesity
pandemic.
This
has
stimulated
active
research
to
develop
novel
NASH
pharmacotherapies
targeting
dysregulated
inflammatory,
cellular
stress,
and
fibrogenetic
processes
include
(1)
metabolic
pathways
improve
insulin
sensitivity,
de
novo
lipogenesis,
mitochondrial
utilization
of
fatty
acids;
(2)
injury
or
inflammatory
targets
reduce
cell
recruitment
signaling;
(3)
liver–gut
axis
influence
bile
acid
enterohepatic
circulation
(4)
antifibrotic
targets.
In
this
review,
we
summarize
several
therapeutic
agents
have
been
studied
in
phase
2
3
randomized
trials.
addition
reviewing
drugs
nuclear
receptor
pathways,
liver
chemokine
receptors,
lipid
metabolism,
lipotoxicity
death,
glucagon-like
peptide-1
also
discuss
rationale
behind
use
combination
therapy
lessons
learned
from
unsuccessful
negative
clinical
Annals of Hepatology,
Journal Year:
2021,
Volume and Issue:
24, P. 100359 - 100359
Published: May 15, 2021
Non-alcoholic
fatty
liver
disease
(NAFLD)
is
reaching
epidemic
proportions
worldwide.
Collectively,
Latin
American
countries
have
some
of
the
highest
obesity
rates
in
world
and
fastest-growing
prevalence
type
2
diabetes
mellitus
(T2DM).
Since
T2DM
are
intrinsically
linked
with
NAFLD,
epidemiological
projections
worrisome.
In
addition
to
this
adverse
setting,
region
America
faces
unique
challenges
obstacles
addressing
growing
burden
NAFLD.
article,
on
occasion
International
NASH
Day
June
10,
2021,
we
describe
main
opportunities
improve
care
people
living
NAFLD
America.
Among
major
be
tackled
are:
lack
awareness,
limited
educational
for
healthcare
personnel
general
public,
health
system
fragmentation,
effective
strategies
prevention
treatment
common
comorbidities,
namely
T2DM.
Wide
dissemination
current
concepts
extensive
collaboration
between
scientific
societies,
governments,
non-governmental
organizations,
pharmaceutical
industry,
other
stakeholders
urgently
needed
advance
public
policies
agenda
that
allows
us
address
a
whole
society
approach.
ACS Nano,
Journal Year:
2021,
Volume and Issue:
15(11), P. 17016 - 17046
Published: Oct. 27, 2021
Nonalcoholic
fatty
liver
disease
(NAFLD),
recently
renamed
metabolic-dysfunction-associated
(MAFLD),
affects
a
quarter
of
the
worldwide
population.
Natural
products
have
been
extensively
utilized
in
treating
NAFLD
because
their
distinctive
advantages
over
chemotherapeutic
drugs,
despite
fact
that
there
are
no
approved
drugs
for
therapy.
Notably,
limitations
many
natural
products,
such
as
poor
water
solubility,
low
bioavailability
vivo,
hepatic
distribution,
and
lack
targeted
effects,
severely
restricted
clinical
application.
These
issues
could
be
resolved
via
drug
delivery
systems
(HTDDS)
boost
efficacy
decrease
adverse
effects
on
other
organs.
Herein
an
overview
comprising
formulas,
single
medicinal
plants,
crude
extracts
has
presented
to
treat
NAFLD.
Also,
molecular
mechanism
active
monomer
compounds
against
systematically
discussed.
The
HTDDS
explored
provide
different
nanotechnology-based
treatment
strategy
make
suggestions
natural-product-based
nanocarrier
design.
Finally,
challenges
opportunities
put
forth
by
nomenclature
update
outlined
along
with
insights
into
how
improve
therapy
design
more
rigorous
nanocarriers
HTDDS.
In
brief,
we
summarize
up-to-date
developments
NAFLD-HTDDS
based
viewpoints
establishment
stringent
anti-NAFLD
natural-product-targeted
nanoformulations.
